AM833 plus semaglutide safe, trims weight in obese/overweight individuals
14 Apr 2021
bởiStephen Padilla
The combination of long-acting amylin analogue AM833 (at all tested doses) and glucagon-like peptide-1 receptor agonist semaglutide (2.4 mg) is well tolerated and shows an acceptable safety profile, with pharmacokinetics data supporting once-weekly dosing, according to a study presented at the virtual conference of the Endocrine Society (ENDO 2021).
AM833 plus semaglutide safe, trims weight in obese/overweight individuals
14 Apr 2021